PT  - JOURNAL ARTICLE
AU  - Sascha, Tierling
AU  - Kathrin, Kattler
AU  - Markus, Vogelgesang
AU  - Thorsten, Pfuhl
AU  - Stefan, Lohse
AU  - Christina, Lo Porto
AU  - Beate, Schmitt
AU  - Abdulrahman, Salhab
AU  - Sigrun, Smola
AU  - Jörn, Walter
TI  - Rapid base-specific calling of SARS-CoV-2 variants of concern using combined RT-PCR melting curve screening and SIRPH technology
AID  - 10.1101/2021.03.15.21253586
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.15.21253586
4099  - http://medrxiv.org/content/early/2021/03/17/2021.03.15.21253586.short
4100  - http://medrxiv.org/content/early/2021/03/17/2021.03.15.21253586.full
AB  - The emergence of novel variants of concern of SARS-CoV-2 demands a fast and reliable detection of such variants in local populations. Here we present a cost-efficient and fast workflow combining a pre-screening of SARS-CoV-2 positive samples using RT-PCR melting curve analysis with multiplexed IP-RP-HPLC-based single nucleotide primer extensions (SIRPH). The entire workflow from positive SARS-CoV-2 testing to base-specific identification of variants requires about 24 h. We applied the sensitive method to monitor the local VOC outbreaks in a few hundred positive samples collected in a confined region of Germany.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Staatskanzlei Saarland (SaarCoSeq) to Sigrun Smola and Joern Walter and the Ministry of Health Saarland (SaarCoMM) to Prof. Smola. Abdulrahman Salhab was supported by the German Federal Ministry of Research and Education grant for de.NBI (031L0101D).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the local ethics committee of the Saarland University Medical Center at Saarland Aerztekammer.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesFasta files of full viral genome sequencing can be accessed on GISAID (https://www.gisaid.org/) using the identifiers listed in Sup. Table 6. https://www.gisaid.org/